From natural products to small molecule ketone histone deacetylase inhibitors: Development of new class specific agents

Current Pharmaceutical Design

Volumn 14, Issue 6, 2008, Pages 545-561

  Jones, Philip ^a   Steinkühler, Christian ^a  

^a IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; AMIDOHYDROLASE INHIBITOR; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; CHLAMYDOCIN; CYCLIC HYDROXAMIC ACID PEPTIDE 1; CYCLIC HYDROXAMIC ACID PEPTIDE 15; CYCLIC HYDROXAMIC ACID PEPTIDE 31; CYCLO[LEUCYLPIPECOLYL (2 AMINO 8 OXO 9,10 EPOXYDECANOYL) DEXTRO PHENYLALANYL]; FR 225497; FR 235222; HC TOXIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; KETONE DERIVATIVE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; ROMIDEPSIN; SHORT CHAIN FATTY ACID; SNDX 275; TRAPOXIN A; TRICHOSTATIN A; TRIFLUOROMETHYL KETONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; DRUG BINDING; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME INHIBITION; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOID LEUKEMIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; VOMITING;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG DESIGN; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; KETONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 42049103914     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208783885317     Document Type: Review

References (123)

1. Roth SY, Denu JM, Allis DC. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
2. Yang XJ. Lysine acetylation and the bromodomain: A new partnership for signaling. Bioessays 2004; 26: 1076-87.
3. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol 2003; 3: 344-51.
4. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell 2006; 126: 257-68.
5. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26: 5420-32.
6. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-52.
7. Boyault C, Sadoul K, Pabion M, Kochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007; 26: 5468-76.
8. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a HDAC homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401:189-93.
9. Vannini A, Volpari C, Gallinari P, Jones P, Mattu M, Carfi A, et al. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep 2007; 8: 879-84.
10. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov 2007; 6: 21.
11. Leder A, Leder P. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 1975; 5: 319-22.
12. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. Butyrate causes histone modification in HeLa and Friend erythroleukemia cells. Nature 1977, 268: 462-4.
13. Novogrodsky A, Dvir A, Ravid A, Shkolnik T, Stenzel KH, Ribin AL, et al. Effect of polar organic compounds on leukemic cells. Cancer 1983; 51: 9-14.
14. Rephaeli A, Zhuk R, Nudelman, A. Prodrugs of butyric acid from bench to bedside: Synthetic design, mechanisms of action, and clinical applications. Drug Dev Res 2000; 50: 379-91.
15. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-79.
16. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276. 36734-41.
17. Lea MA; Tulsyan N. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res 1995; 15: 879-83.
18. (a) Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003; 46: 5097-116.
19. (b) Rodriquez M, Aquino M, Bruno I, Martino GD, Taddei M, Gomez-Paloma L. Chemistry and biology of chromatin remodeling agents: State of art and future perspectives of HDAC inhibitors. Curr Med Chem 2006; 13: 1119-39.
20. (c) Moradei O, Maroun CR, Paquin I, Vaisburg A. Histone deacetylase inhibitors: Latest developments, trends and prospects. Curr Med Chem Anticancer Agents 2005; 5: 529-60
21. (d) Meinke PT, Liberator P. Histone deacetylase: A target for antiproliferative and antiprotozoal agents. Curr Med Chem 2001; 8: 211-35.
22. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K. A new antifungal antibiotic, trichostatin. J Antibiotics (Tokyo) 1976; 29: 1-6.
23. Morioka H, Ishihara M, Takezawa M, Hirayama K, Suzuki E, Komoda Y, et al. A new differentiation inducer of Friend leukemia cells, trichostatic acid. Agric Biol Chem 1985; 49: 1365-70.
24. Yoshida M, Iwamoto Y, Uozumi T, Beppu T. Trichostatin C, a new inducer of differentiation of Friend leukemic cells. J Antibiotics (Tokyo) 1985; 49: 563-5.
25. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian HDAC both in vivo and in vitro by TSA. J Biol Chem 1990; 265: 17174-9.
26. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93: 5705-8.
27. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003-7.
28. Kelly WK, Marks PA. Drug insight: HDACi - development of the new targeted anticancer agent SAHA. Nat Clin Pract Oncol 2005; 2: 150-7.
29. Richon VM. Cancer biology: Mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 2006; 95: S2-6.
30. Duvic M, Zhang C. Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. Br J Cancer 2006; 95: S13-9.
31. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26: 1351-6.
32. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-15.
33. Remiszewski SW. The discovery of NVP-LAQ824: From concept to clinic. Curr Med Chem 2003; 10: 2393-402.
34. Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, et al. N-Hydroxy-3-phenyl-2-propenamides as novel inhibitors of human HDAC with in vivo antitumor activity: discovery of NVP-LAQ824. J Med Chem 2003; 46: 4609-24.
35. Ottmann OG, Deangelo DJ, Stone RM, Pfeifer H, Lowenberg B, Atadja P, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. J Clin Oncol 2004; 22 (14S): 3024.
36. Prince HM, George DJ, Johnstone R, Williams-Truax R, Atadja P, Zhao C, et al. LBH589, a novel histone deacetylase inhibitor (HDACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Changes in skin gene expression profiles related to clinical response following therapy. J Clin Oncol 2006; 24 (18S): 7501.
37. Finn PW, Bandara M, Butcher C, Finn A, Hollinshead R, Khan N, et al. Novel sulfonamide derivatives as inhibitors of histone deacetylase. Helv Chim Acta 2005; 88: 1630-57.
38. Plumb JA; Finn PW, Williams RJ, Bandara MJ; Romero MR, Watkins CJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel historic deacetylase inhibitor PXD101. Mol Cancer Ther 2003; 2: 721-8.
39. Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, et al. CRA-024781: A novel synthetic inhibitor of HDAC enzymes with antitumor activity in vitro and in vivo. Mol Cane Ther 2006; 5: 1309-17.
40. Fong PC, Settatree S, Sinha R, Hardcastle A, Hellemans PW, Arts J, et al. A first-in-man phase I study of R306465, a histone deacetylase (HDAC) inhibitor exploring pharmacokinetics (PK) and pharmacodynamics (PD) utilizing an electrochemiluminescent immunoassay in patients (p) with advanced tumours. J Clin Oncol 2007; 25 (18S): 3578.
41. (a) van Emelen K, Arts J, Angibaud P, de Winter H, Poncelet V, Marien A, et al. The identification of a novel series of N-hydroxybenzamides as potent HDAC inhibitors: Synthesis, biological evaluation and structure activity relationships. CNIO Cancer Conference, Medicinal Chemistry in Oncology, Madrid, Spain. 2-4 October 2006.
42. (b) Arts J, Angibaud P, Mariën A, Floren W, Janssens B, King P, et al. R306465 is a novel potent inhibitor of class I HDACs with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 2007; 97: 1344-53.
43. Berger MR, Bischoff H, Fritschi E, Henne T, Hermann M, Pool BL, et al. Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2′-aminophenyl)-benzamide: A new compound preferentially active in slowly growing tumors. Cancer Treat Rep 1985; 69: 1415-24.
44. Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flahery L, et al. Chronic oral administration of CI-994: A phase I study. Invest New Drugs 2001; 19: 1-11.
45. Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Merriman RL. Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Can Ther 2003; 2: 401-8.
46. Hauschild A. A phase II multicenter study on the HDACi MS-275, comparing two dosage schedules in metastatic melanoma Abs. 8044. Ann Meet Am Soc Clin Oncol Atlanta, Ga. 2006.
47. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, et al. Synthesis and historic deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999; 42: 3001-3.
48. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, et al. A synthetic inhibitor of HDAC, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592-7.
49. Hess-Stump H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases - The development of an anticancer agent. Int J Biochem Cell Biol 2007; 39: 1388-405.
50. Moradei O, Leit S, Zhou N, Frechétte S, Paquin I, Raeppel S, et al. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: Novel classes of histone deacetylase inhibitors. Bioorg Med Chem Lett 2006; 16: 4048-52.
51. Vaisburg A. Discovery and development of MGCD0103 - an orally active HDAC inhibitor in human clinical trials. X1Xth Int Sym, Med Chem Istanbul Aug 2006.
52. Kell J. Drug evaluation: MGCD-0103, a histone deacetylase inbibitor for the treatment of cancer. Curr Opin Invest Drugs 2007; 8: 485-92.
53. (a) Moradei OM, Mallais TC, Frechette S, Paquin I, Tessier PE, Leit SM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem 2007; 50: 5543-6.
54. (b) Miller TA. Histone deacetylase inhibitors: Bench to bedside. COMC-108, Frontiers in CNS and oncology medicinal chemistry, Siena, Italy. 7th-9th October 2007.
55. (c) Wilson KJ, Witter DJ, Siliphaivanh P, Otte K, Kral AM, Fleming J, et al. Discovery and optimization of novel HDAC inhibitors. COMC-050, Frontiers in CNS and oncology medicinal chemistry, Siena, Italy. 7th-9th October 2007.
56. (d) Witter DJ, Harrington P, Wilson KJ, Chenard M, Fleming JC, Haines B, et al. Optimization of biaryl selective HDAC 1 & 2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 2008; 18: 726-31.
57. Haggarty SJ, Koeller KM, Wong JC, Butcher RA, Schreiber SL. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem Biol 2003; 10: 383-96.
58. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of HDAC6-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003; 100: 4389-94.
59. Pringle RB. Amino acid composition of the host-specific toxin of Helminthosporium carbonum. Plant Physiol 1971; 48: 756-9
60. Liesch JM, Sweeley CC, Staffeld GD, Anderson MS, Weber DJ, Scheffer RP. Structure of HC-toxin, a cyclic tetrapeptide from helminthosporium carbonum. Tetrahedron 1982; 38: 45-8.
61. Pope MR, Ciuffetti LM, Knoche HW, McCrery D, Daly JM, Dunkle LD. Structure of the host-specific toxin produced by Helminthosporium carbonum. Biochemistry 1983; 22: 3502-6.
62. Gross ML, McCrery D, Crow F, Tomer KB, Pope MR, Ciuffetti LM, et al. The structure of the toxin from helminthosporium carbonum. Tetrahedron Lett 1982; 23: 5381-4.
63. Walton JD. HC-toxin. Phytochemistry 2006; 67: 1406-13.
64. Brosch G, Ransom R, Lechner T, Walton, JD, Loidl P. Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Plant Cell 1995; 7: 1941.
65. Kim S-D, Knoche HW, Dunkle LD, McCrery DA, Tomer, KB. Structure of an amino acid analog of the host-specific toxin from helminthosporium carbonum. Tetrahedron Lett 1985, 26, 969-72.
66. Tanis SP, Horenstein BA, Scheffer RP, Rasmussen JB. A new host specific toxin from Helminthosporium Carbonum. Heterocycles 1986; 24: 3423-31.
67. Rasmussen JB, Scheffer RP. Isolation and biological activities of four selective toxins from Helminthosporium carbonum. Plant Physiol 1988; 86: 187-91.
68. Closse A, Huguenin R. Isolierung und Strukturaufkiärung von Chlamydocin. Helv Chim Acta 1974; 57: 533-45.
69. Gupta S, Peiset G, Nakajima T, Hwang Y-S. Characterization of a phytotoxic cyclotetrapeptide, a novel chlamydocin analogue, from Verticillium coccosporum. Tetrahedron Lett 1994; 35: 6009-12.
70. De Schepper S, Bruwiere H, Verhulst T, Steller U, Andries L, Wouters W, et al. Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin. J Pharmacol Exp Ther 2003; 304: 881-8.
71. Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, et al. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiotics (Tokyo) 1990: 43: 1524-32.
72. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T, Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 1993; 268: 22429-35.
73. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996; 272: 408-11.
74. Taunton J, Collins JL, Schreiber SL. Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. J Am Chem Soc 1996; 118: 10412-22.
75. Mori H, Yoshimura S, Takase S, Hino M. Cyclic tetrapeptide FR225497 from Helicoma, pharmaceutical composition, and use for inhibition of histone deacetylase and treatment of diseases. WO2000/08048, 2000.
76. Hirota A, Suzuki A, Suzuki H, Tamura S. Isolation and biological activity of Cyl-2, a metabolite of Cylindrocladium scoparium. Agric Biol Chem 1973; 37: 643-7.
77. Hirota A, Suzuki A, Aizawa K, Tamura S. Structure of Cyl-2, a novel cyclotetrapeptide from Cylindrocladium scoparium. Agric Biol Chem 1973; 37: 955-6.
78. Hirota A, Suzuki A, Tamura S. Characterization of four amino acids constituting Cyl-2, a metabolite from Cylindrocladium scoparium. Agric Biol Chem 1973; 37: 1185-9.
79. Umehara K, Nakahara M, Kiyoto S, Iwami, M, Okamoto M,, Tanaka H, et al. Studies on WF-31 1, a new antitumor antibiotic. J Antibiot (Tokyo) 1983; 36: 478-83.
80. Kawai M, Pottorf RS, Rich DH. Structure and solition conformation of the cytostatic cyclic tetrapeptide WF-3161, cyclo [L-leucyl- L-pipecolyl-L-(2-amino-8-oxo-9,10-epoxydecanoyl)-D-phenyl alanyl]. J Med Chem 1986; 29: 2409-11.
81. Yoshimura K, Tsuboya S, Okszaki K. Neoplasm inhibitors manufacture with Verticillium chlamydosporium. JP7196686, 1995.
82. Mori H, Urano Y, Abe F, Furukawa S, Furukawa S, Tsurumi Y, et al. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian historic deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo) 2003; 56: 72-9.
83. Mori H, Abe F, Furukawa S, Furukawa S, Sakai F, Hino M, et al. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). II. Biological activities in animal models. J Antibiot (Tokyo) 2003; 56: 80-6.
84. Nakao Y, Yoshida S, Matsunaga S, Shindoh N, Terada Y, Nagai K, et al. Azumamides A-E: Histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge mycale izuensis. Angew Chem Int Ed Engl 2006; 45: 7553-7.
85. Wen S, Carey KL, Nakao Y, Fusetani N, Packman G, Ganesan A. Total synthesis of azumamide a and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue. Org Lett 2007; 9: 1105-8.
86. Maulucci N, Chini MG, Di Micco S, Izzo I, Cafaro E, Russo A, et al. Molecular insights into azumamide E histone deacetylases inhibitory activity. J Am Chem Soc 2007; 129: 3007-12.
87. Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM, Allocco JJ, et al. Apicidin: A novel antiprotozoal agent that inhibit parasite HDAC. Proc Natl Acad Sci USA 1996; 93: 13143-7.
88. WAF1/Cip1 and gelsolin. Cancer Res 2000; 60: 6068-74.
89. Singh SB, Zink DL, Liesch JM, Mosley RT, Dombrowski AW, Bills GF, et al. Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal α-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J Org Chem 2002; 67: 815-25.
90. Colletti SL, Myers RW, Darkin-Rattray SJ, Gurnett AM, Dulski PM, Galuska S, et al. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: Structure-activity relationships of apicidin. Part 1. Bioorg Med Chem Lett 2001; 11: 107-12.
91. Colletti SL, Myers RW, Darkin-Rattray SJ, Gurnett AM, Dulski PM, Galuska S, et al. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: Structure-activity relationships of apicidin. Part 2. Bioorg Med Chem Lett 2001; 11: 113-7.
92. Meinke PT, Colletti SL, Doss G, Myers RW, Gurnett AM, Dulski PM, et al. Synthesis of apicidin -derived quinolone derivatives: parasite-selective histone deacetylase inhibitors and anti-proliferative agents. J Med Chem 2000; 43: 4919-22.
93. Ueda M, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994; 47: 301-10.
94. Shigematsu N, Ueda M, Takase S, Tanaka H, Yamamoto K, Tada T. FR901228, a novel antitumor bicyclic, depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J Antibiot (Tokyo) 1994; 47: 310-14.
95. Ueda M, Manda. T, Matsumoto S, Mukurnoto S, Nishigaki F, Kawamura I, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994; 47: 315-23.
96. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998; 241: 126-33.
97. Furumai R, Matsuyama A, Kobashi N, Lee K-H, Nishiyama M, Nakajima H, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I HDACs. Cancer Res 2002; 62: 4916-21.
98. Whittaker, S. International multicenter phase II study of the HDAC inhibitor (HDACi) depsipeptide (FK228) in cutaneous T-cell lymphoma (CTCL): Interim report. Abs. 3063, Ann Meet Am See Clin Oncol Atlanta, Ga. 2006.
99. Masuoka Y, Nagai A, Shin-ya K, Furihata K, Nagai K, Suzuki K, et al. Spiruchostatins A and B, novel gene expTession-enhancing substances produced by Pseudomonas sp. Tetrahedron Lett 2001; 42: 41-4.
100. Yurek-George A, Habens F, Brimell M, Packman G, Ganesan A. Total synthesis of spiruchostatin a, a potent histone deacetylase inhibitor. J Am Chem Soc 2004; 126: 1030-1.
101. Mays JR, Restituyo JA, Katzenberger RJ, Wassarman DA, Rajski SR. Cyclic disulfides as functional mimics of the histone deacetylase inhibitor FK-228. Tetrahedron Lett 2007; 48: 4579-83.
102. waf1/cip1 expression in human colon tumor cell lines. Carcinogenesis 2004; 25: 1227-36.
103. Pina IC; Gautschi JT, Wang G-Y-S, Sanders ML, Schmitz FJ, France D, et al. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 2003; 68: 3866-73.
104. Park Y, Liu Y, Hong J, Lee C-O, Cho H, Kim D, et al. New Bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis. J Nat Prod 2003; 66: 1495-8.
105. Kim DH, Shin J, Kwon HJ. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp Mol Med2007; 39: 47-55.
106. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 2001; 98: 87-92.
107. Komatsu Y, Tomizaki K, Tsukamoto M, Kato T, Nishino N, Sato S, et al. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res 2001; 61: 4459-66.
108. Nishino N, Jose B, Okamura S, Ebisusaki S, Kato T, Sumida Y, et al. Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases. Org Lett 2003; 5: 5079-82.
109. Jose B, Oniki Y, Kato T, Nishino N, Sumida Y, Yoshida M. Novel histone deacetylase inhibitors: Cyclic tetrapeptide with trifluoromethyl and pentaflouroethyl ketones. Bioorg Med Chem Lett 2004; 14: 5343-6.
110. Bhuiyan MPI, Kato T, Okauchi T, Nishino N, Maeda S, Nishino TG, et al. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg Med Chem 2006; 14: 3438-46.
111. Frey RR, Wada CK, Garland RB, Curtin ML; Michaelides MR, Li J, et al. Trifluoromethyl ketones as inhibitors of HDAC. Bioorg Med Chem Lett 2002; 12: 3443-7.
112. Vasudevoin A, Ji Z, Frey RR, Wada CK, Steinman D, Heyman HR, et al. Heterocyclic ketones as inhibitors of HDAC. Bioorg Med Chem Lett 2003; 13: 3909-13.
113. Wada CK, Frey RR, Ji Z, Curtin ML, Garland RB, Holms JH, et al α-Keto amides as inhibitors of HDAC. Bioorg Med Chem Lett 2003; 13: 3331-5.
114. Jones P, Altamura S, Chakravarty PK, Cecchetti O, De Francesco R, Gallinari P, et al. A seines of novel, potent, and selective histone deacetylase inhibitors. Bioorg Med Chem Lett 2006; 16: 5948-52.
115. Jones P, Altamura S, De Francesco R, Gonzalez Paz O, Kinzel O, Mesiti G, et al. A novel series of potent and selective ketone histone deacetylase inhibitors with anti-tumor activity in vivo. J Med Chem 2008; submitted.
116. Lahm, A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P, et al. Unraveling the hidden catalytic activity of vertebrate class IIA histone deacetylases. Proc Natl Acad Sci USA 2007; 104: 17335-40.
117. Jones P, Altamura S, De Francesco R, Gallinari P, Lahm A, Neddermann P, et al. Probing the elusively catalvtic activity of vertebrate class IIa histone deacetylases. Bioorg Med Chem Lett 2008; accepted.
118. Jones P, Bottomley MJ, Carfi A, Cecchetti O, Ferrigno F, Lo Surdo P, et al. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg Med Chem Lett 2008; accepted.
119. Bottomley MJ,Lo Surdo P,Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, et al. Structure of human class IIa Histone Deacetylase 4 catalytic domain reveals a conserved regulatory zinc-binding domain. Proc Natl Acad Sci USA 2008; submitted.
120. Davis D, Kim HM, Ramphal JY, Spencer JR, Tai VWF, Verner EJ. Silanol derivatives as inhibitors of histone deacetylase and their preparation, pharmaceutical compositions, and treatment of histone deacetylase associated diseases. W02006/069096,2006.
121. Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU. Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. Curr Pharm Des 2006; 12(1): 111-28.
122. Elaut G, Rogiers V, Vanhaecke T. The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des 2007; 13(25): 2584-620.
123. Papaetis GS, Roussos C, Syrigos KN. Targeted therapies for non-small cell lung cancer. Curr Pharm Des 2007; 13(27): 2810-31.